Roche (RHHBY.US) invests an additional $4 billion in the field of IBD, developing pre-clinical oral small molecules.

According to Wisdom Finance APP, on September 2nd, OMass Therapeutics announced that it has reached an exclusive collaboration and licensing agreement with Genentech, a member of the Roche Group (RHHBY.US), to develop and commercialize OMass' preclinical oral small molecule project for the treatment of inflammatory bowel disease (IBD). OMass is a biotechnology company that develops drugs targeting highly validated targets such as membrane proteins or intracellular complexes.